BMS-955176 is an experimental HIVmaturation inhibitor under development by Bristol-Myers Squibb for use in the treatment of HIV infection. By blocking the maturation of the virus, it prevents viral reproduction in host CD4+ T cells.[1] Because it targets a different step of the viral lifecycle, it offers promise for individuals with virus that has become highly resistant to other classes of HIV drugs.[2] Since this drug better handles naturally occurring changes in the Gag protease polyprotein, it is unlikely to promote resistance to itself unlike earlier maturation inhibitors.[3]
